US Patent issued for new multi-functional thermal ablation device

Patent covers new medical device technology developed by CPSI Biotech capable of delivering both heat and cryogenic energy for tissue ablation in a single device

March 6, 2017

OWEGO, NY -- CPSI Biotech is proud to announce the issuance of a patent (US Pat#: 9,566,105) by the United States Patent and Trademark Office covering device design and method of use of a new multi-functional thermal ablation technology to be used for the treatment of diseases ranging from cancer or heart disease.

This multi-functional thermal ablation technology offers the ability to apply both heat and cryogenic energy to tissue using a single device, enabling controlled, real-time application of a dual thermal ablation strategy. The dual thermal ablation system enables the delivery of a multitude of therapeutic treatment options, including heat and cold, along with anti-cancer agents, alone or in any combination as desired. Dr. John M. Baust, President and Chief Executive Officer of CPSI Biotech, stated “This technological platform will offer a physician the ability to apply both heat and cryotherapy in conjunction or alone, all from a single probe to ablate targeted tissue. The ability to deliver multiple ablative energy insults in a single device will eliminate the need for multiple systems and probe switching during a procedure, thereby reducing patient risk, procedure time and overall cost.”

When asked to comment on the technology and its use in applications, Dr. Kristi Snyder (Principal Scientist at CPSI) stated “One interesting scientific aspect of this technology is that each of the modes of thermal ablation impact targeted cells through different mechanisms to achieve cell death. Recent studies have shown that the approach of both heat and cryoablation in tandem results in improved destruction of multiple types of cancer, including pancreatic cancer, as well as cardiac tissue. As such, by leveraging the ease of applying dual thermal ablation using this technology may provide for improved clinical outcome.”

Regarding CPSI Biotech’s future plans for the technology, Baust stated, “We continue to work on the development of this innovative technology. Our goal is to move through the R&D phase and into pilot studies with a clinical collaborator with this technology over the next year.”

About CPSI Biotech - CPSI Biotech, a private, integrative bio/medtech greenhouse company, develops and designs life science research products and cryo-medical devices for applications in cancer, cardiovascular disease treatments and cell therapy bioprocessing. Ongoing R&D and business development activities continue to produce innovative technologies, devices and intellectual property for commercialization, licensing or sales in support of diverse clinical and research applications. By leveraging the innovation, flexibility and R&D strengths of CPSI in combination with the development, commercialization, manufacturing and clinical expertise of partnering organizations, rapid and efficient product development is attainable.
Disclosure Notice: The information contained in this release is as of March 6, 2017. CPSI assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. CPSI’s technologies do not have regulatory clearance for commercial sale and are currently intended for “Research Use Only”.

With the exception of the historical information contained in this release, this release contains materials and statements related to future business, financial performance, future events and/or developments involving CPSI which constitute forward-looking statements. The matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to, CPSI’s ability to develop and market new products, to retain and attract key employees, to obtain regulatory clearances and approvals for its products, to effectively react to other risks and uncertainties, such as fluctuation of quarterly financial results, contract and grants acquisition, reliance on third party manufacturers and suppliers, litigation or other proceedings, economic, competitive, governmental impacts, whether pending patents will be granted or defendable, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, competition from existing and new products and procedures and CPSI’s ability to raise the capital that is required to accomplish the foregoing.

Contact:
CPSI Biotech
John M Baust, Ph.D., President & Lead Scientist
Kristi Snyder, Ph.D., Director of Operations
Email: contact@cpsibiotech.com
Website: www.cpsibiotech.com